The effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson's disease

Karl Kieburtz, M. McDermott, P. Como, J. Growdon, J. Brady, Julie Carter, S. Huber, B. Kanigan, E. Landow, A. Rudolph, J. Saint-Cyr, Y. Stern, M. Tennis, J. Thelen, I. Shoulson

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

We conducted prospective cognitive assessments over 14 k 6 (mean SD) months of observation as part of the multicenter trial Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), which involved 800 patients with early untreated Parkinson's disease. We administered tests that measured memory, visuospatial, and frontal lobe functions. Subjects were randomly assigned to receive placebo, deprenyl(10 mg/d), tocopherol (2,000 IU/d), or both deprenyl and tocopherol. We analyzed treatment effects using annualized rates of cognitive change. We performed exploratory analyses to identify potential clinical and demographic correlates of cognitive performance. There was no significant effect of either deprenyl or tocopherol on cognitive test performance. In early untreated Parkinson's disease, cognitive performance appears to be stable and unrelated to either motor deterioration or treatment with deprenyl or tocopherol.

Original languageEnglish (US)
Pages (from-to)1756-1759
Number of pages4
JournalNeurology
Volume44
Issue number9
StatePublished - 1994

Fingerprint

Selegiline
Tocopherols
Parkinson Disease
Parkinsonian Disorders
Frontal Lobe
Multicenter Studies
Therapeutics
Placebos
Observation
Demography
Cognitive Performance
Parkinson's Disease

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Kieburtz, K., McDermott, M., Como, P., Growdon, J., Brady, J., Carter, J., ... Shoulson, I. (1994). The effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson's disease. Neurology, 44(9), 1756-1759.

The effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson's disease. / Kieburtz, Karl; McDermott, M.; Como, P.; Growdon, J.; Brady, J.; Carter, Julie; Huber, S.; Kanigan, B.; Landow, E.; Rudolph, A.; Saint-Cyr, J.; Stern, Y.; Tennis, M.; Thelen, J.; Shoulson, I.

In: Neurology, Vol. 44, No. 9, 1994, p. 1756-1759.

Research output: Contribution to journalArticle

Kieburtz, K, McDermott, M, Como, P, Growdon, J, Brady, J, Carter, J, Huber, S, Kanigan, B, Landow, E, Rudolph, A, Saint-Cyr, J, Stern, Y, Tennis, M, Thelen, J & Shoulson, I 1994, 'The effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson's disease', Neurology, vol. 44, no. 9, pp. 1756-1759.
Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson's disease. Neurology. 1994;44(9):1756-1759.
Kieburtz, Karl ; McDermott, M. ; Como, P. ; Growdon, J. ; Brady, J. ; Carter, Julie ; Huber, S. ; Kanigan, B. ; Landow, E. ; Rudolph, A. ; Saint-Cyr, J. ; Stern, Y. ; Tennis, M. ; Thelen, J. ; Shoulson, I. / The effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson's disease. In: Neurology. 1994 ; Vol. 44, No. 9. pp. 1756-1759.
@article{1dda24d5064a4174a060644a17790ebb,
title = "The effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson's disease",
abstract = "We conducted prospective cognitive assessments over 14 k 6 (mean SD) months of observation as part of the multicenter trial Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), which involved 800 patients with early untreated Parkinson's disease. We administered tests that measured memory, visuospatial, and frontal lobe functions. Subjects were randomly assigned to receive placebo, deprenyl(10 mg/d), tocopherol (2,000 IU/d), or both deprenyl and tocopherol. We analyzed treatment effects using annualized rates of cognitive change. We performed exploratory analyses to identify potential clinical and demographic correlates of cognitive performance. There was no significant effect of either deprenyl or tocopherol on cognitive test performance. In early untreated Parkinson's disease, cognitive performance appears to be stable and unrelated to either motor deterioration or treatment with deprenyl or tocopherol.",
author = "Karl Kieburtz and M. McDermott and P. Como and J. Growdon and J. Brady and Julie Carter and S. Huber and B. Kanigan and E. Landow and A. Rudolph and J. Saint-Cyr and Y. Stern and M. Tennis and J. Thelen and I. Shoulson",
year = "1994",
language = "English (US)",
volume = "44",
pages = "1756--1759",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - The effect of deprenyl and tocopherol on cognitive performance in early untreated parkinson's disease

AU - Kieburtz, Karl

AU - McDermott, M.

AU - Como, P.

AU - Growdon, J.

AU - Brady, J.

AU - Carter, Julie

AU - Huber, S.

AU - Kanigan, B.

AU - Landow, E.

AU - Rudolph, A.

AU - Saint-Cyr, J.

AU - Stern, Y.

AU - Tennis, M.

AU - Thelen, J.

AU - Shoulson, I.

PY - 1994

Y1 - 1994

N2 - We conducted prospective cognitive assessments over 14 k 6 (mean SD) months of observation as part of the multicenter trial Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), which involved 800 patients with early untreated Parkinson's disease. We administered tests that measured memory, visuospatial, and frontal lobe functions. Subjects were randomly assigned to receive placebo, deprenyl(10 mg/d), tocopherol (2,000 IU/d), or both deprenyl and tocopherol. We analyzed treatment effects using annualized rates of cognitive change. We performed exploratory analyses to identify potential clinical and demographic correlates of cognitive performance. There was no significant effect of either deprenyl or tocopherol on cognitive test performance. In early untreated Parkinson's disease, cognitive performance appears to be stable and unrelated to either motor deterioration or treatment with deprenyl or tocopherol.

AB - We conducted prospective cognitive assessments over 14 k 6 (mean SD) months of observation as part of the multicenter trial Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), which involved 800 patients with early untreated Parkinson's disease. We administered tests that measured memory, visuospatial, and frontal lobe functions. Subjects were randomly assigned to receive placebo, deprenyl(10 mg/d), tocopherol (2,000 IU/d), or both deprenyl and tocopherol. We analyzed treatment effects using annualized rates of cognitive change. We performed exploratory analyses to identify potential clinical and demographic correlates of cognitive performance. There was no significant effect of either deprenyl or tocopherol on cognitive test performance. In early untreated Parkinson's disease, cognitive performance appears to be stable and unrelated to either motor deterioration or treatment with deprenyl or tocopherol.

UR - http://www.scopus.com/inward/record.url?scp=0028025072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028025072&partnerID=8YFLogxK

M3 - Article

C2 - 7936311

AN - SCOPUS:0028025072

VL - 44

SP - 1756

EP - 1759

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -